Bristol Myers Squibb receives European approval for subcutaneous formulation of Opdivo across multiple solid tumour ...
Bristol Myers Squibb announced that the European Commission (EC) has approved a new Opdivo (nivolumab) formulation associated with a new route of administration (subcutaneous use [SC]), a new pharmaceutical form (solution for injection) and a new strength …